HOME > MEDICAL CENTER  > CV of Bruce Miller

Medline || Bookstore || Conferences || Email Us || Contact Us || Glossary || Links || Scuba Clinic Forum  || Tenfootstop Weblog || FAQ

Search This Site

Comprehensive information about diving and undersea medicine for the non-medical diver, the non-diving physician and the specialist.

---

BRUCE H. MILLER, M.D.

CURRICULUM VITAE

April 2006

CURRENT MEDICAL PRACTICE:

OREGON MEDICAL RESEARCH CENTER, P.C.

FAX (503)245-0315

E-mail: ormedresearch@aol.com

Office devoted strictly to new dermatology drug research. Principal Investigator or Sub-Investigator for over 500 studies from 1995 to date. Lecturer USA & England for 8 pharmaceutical companies.

Private Dermatology Practice 1970-1995 

Dermatology Associates, P.C. 

9495 SW Locust Street, Suite A 

Portland, OR 97223

Conducted dermatology new drug research during this time. Principal Investigator for over 40 studies from 1975 to 1995.

Clinical Professor, Department of Dermatology

Oregon Health Sciences University

Portland, OR

Courtesy Hospital Staff

Oregon Health Sciences University Hospital

Portland, OR

MEDICAL LICENSURE:

OREGON #MD07694

CALIFORNIA #G11439

OHIO #27386 (Inactive)

BOARD CERTIFICATIONS:

Eligible – Internal Medicine

Diplomate – National Board of Medical Examiners, #71361

Diplomate – American Board of Dermatology, 1970

Diplomate – American Board of Dermatopathology, 1978

EDUCATION:

Undergraduate: Amherst College – B.A. English, 1959

Medical School: State University of New York, Downstate Medical Center M.D., 1963

Internship: Ohio State University Hospitals – Straight Medical, 1963-1964

Residency: Ohio State University Hospitals – One Year Medical, 1964-1965

Oakland Naval Hospital – One Year Medical, 1966

University Hospitals of Cleveland (Case Western Reserve University) Dermatology, 1967-1970

Teaching Fellow, Department of Internal Medicine, 1970

Military: U.S. Navy – Long Beach, CA – Troop Ship and Oakland Naval Hospital,

Honorable Discharge, 1969

PROFESSIONAL ACTIVITIES:

MEMBERSHIPS – Partial List

Oregon Dermatological Society, President 1983-1984

Pacific Northwest Dermatology Association, President 1978-1979

Associates of Clinical Pharmacology

Pacific Dermatology Association

American Academy of Dermatology, Fellow

American Society of Dermatological Surgery, Fellow

International Society of Dermatopathology

Multnomah County Medical Society

Oregon Medical Association

American Medical Association

Association of Clinical Research Professionals

CLINICAL DRUG STUDIES

Sytex Johnson & Johnson Allergan Herbert

Matrix Rhone-Poulenc Rorer ISIS

Galderma Merck Shaman

Magainin Connetics TAP Holdings

Stiefel Dermik Advanced Tissue Sciences

Dow Glaxo Xoma

Novartis Roche Genentech

Ortho-McNeil Bristol-Myers Squibb Research Testing Laboratories

Atrix Bayer Parke-Davis

IDEC 3M Human Genome Sciences

Immunex MedImmune Schering Plough

Berlex Pfizer Centocor

Corixa Genetics Institute Boehringer Ingelheim

Medicis HealthPoint Cellgate

MediGene Wyeth Abbott

Fujisawa TolerRx Synta

Serono CombinatoRx Ferndale

ADVISORY BOARDS (2003) SPEAKERS BUREAUS (2003)

Genentech Atrix Immunex/Amgen Genentech

Chemgenics Allergan/Proctor Gamble

Page 2 of 5

BIBLIOGRAPHY: (Since 1998)

Papp, K., B. Miller, et.al. “Efalizumab Retreatment in Patients with Moderate to Sever Chronic Plaque Psoriasis.” Journal of the American Academy of Dermatology, 2006;4:54.

Breneman, D., B. Miller, et.al. “Clobetasol Propionate 0.05% Lotion in the Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Evaluation Versus Clobetasol Propionate Emollient Cream.” Journal of Drugs in Dermatology, May/June 2005.

Shalita, A., B. Miller, et.al. “Tazarotene Cream versus Adapalene Cream in the Treatment of Facial Acne Vulgaris: A Multicenter, Double-Blind, Randomized, Parallel-Group Study.” Journal of Drugs in Dermatology, 2005;4:153-158.

Miller, B., R.T. Matheson, et. al. “The Evaluation of Maintenance Therapy of Differin® Gel, 0.1 % Vs Vehicle in Subjects with Acne Vulgaris.” Archives of Dermatology, Manuscript, 2005.

Lowe, N.J., A. Menter , B.H. Miller et al. “Oral Tazarotene in the Treatment of Moderate to Severe Plaque Psoriasis: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Followed by One Double-Blind and Two Open-Label Dose-Escalation Extensions.” Journal of the American Academy of Dermatology, 2003.

Leyden, D., E. Tanghetti, B. Miller, et al. “Once-Daily Tazarotene 0.1% Gel Versus Once-Daily Tretinoin 0.1% Microsponge in the Treatment of Facial Acne Vulgaris: A Double-Blind, Randomized Trial.” Cutis, 2002;69(suppl 2):12-19.

Lowe, N.J., A. Menter, B. Miller, et. al. “Dose-Escalation Study of Oral Tazarotene in the Treatment of Moderate to Severe Plaque Psoriasis.” The Lancet, Research Letter, January, 2002.

Ring, J., B. Miller, et. al. “Once-Daily Desloratadine Improves the Sign and Symptoms of Chronic Idiopathic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Study.” International Journal of Dermatology, 2001;40:72-76.

Gottlieb, A., B. Miller, et. al. “Clinical Efficacy, Safety, and Biologic Activity of Subcutaneously Administered Anti-CD11a (Efalizumab) in Patients With Psoriasis.” Journal of Cutaneous Medicine and Surgery, 2001.

Miller, B.H., et. al. “Sparfloxacin Versus Ciprofloxacin for Treating Community-Acquired Complicated Skin and Skin Structure Infection.” April 1999.

Leyden, D., F. Dunlap, B. Miller, et. al. “Finasteride in the Treatment of Men with Frontal Male Pattern Hair Loss.” Journal of the American Academy of Dermatology, 1999;40:930-7.

Swinehart J.M., R. B. Skinner, B. Miller et. al. “Development of Intralesional Therapy with Fluorouracil/Adrenalin Injectable Gel for Management of Condylomata Acuminata: Two Phase II Clinical Studies.” Genitourinary Medicine, October 1998.

Shalita, A., B.H. Miller, et. al. “Tazarotene Gel is Safe and Effective in the Treatment of Acne Vulgaris: A Multicenter, Double-Blind, Vehicle-Controlled Study.” Archives of Dermatology, submitted July 1998.

Page 3 of 5

Kraus S., B.H. Miller, et. al. “Intratumoral Chemo-Therapy with Fluorouracil/Epinephrine Injectable Gel: A Non-Surgical Treatment of Cutaneous Squamous Cell Carcinoma.” Journal American Academy of Dermatology, 1998;38:438-442.

LECTURES AND PRESENTATIONS: (Since 1997)

Continuing Education for Physicians, Portland, OR, February 2003. (Sponsored by Proctor and Gamble) “Tazorac in Treating Acne”

Teleconferences for Physicians - Presenter and Moderator (Sponsored by Allergan Pharmaceuticals approximately 6 times/year, 1999-2002). “Tazorac and Acne”

RTL Sponsored Investigator’s Meeting, Tucson, AZ, January, 2002. “Pathophysiology of Acne”

RTL Sponsored Investigator’s Meeting, Orlando, FL, June, 2001. “Tinea Versicolor: An Overview”

Oregon Medical Association, “Loss Prevention Video Series 1-4”. Filmed for use with all physicians in Oregon. February, 1997 and May, 2000.

Society for Investigative Dermatology, Annual Meeting, Chicago, IL, May 10, 2000. “Clinical and Histologic Effects of Subcutaneously Administered Anti-CD11a (hu1124) in Patients with Psoriasis”

Tricounty Dermatology Society, Annual Meeting, Ojai, CA, November 13, 1998. “Tazarotene-New Approach to Treating Psoriasis” and “Medical Preparedness for Remote Travel”

Sacramento County Dermatology Society, Annual Meeting, Napa, CA, October 1998. “New Approaches to Treating Psoriasis” and “Medical Preparedness for Remote Travel”

Kansas City Dermatology Society, July 17, 1998. “Tazarotene - New Approach to Treating Psoriasis,” Nail Disease Lecture to Residents, Patient Discussions

Medical Seminars: Medicine of Diving, Palau, Micronesia, April, 1998. Faculty, “Photodermatoses of the Skin”

Western Carolina Dermatology Society, Annual Meeting, Asheville, NC, March 1998. (Sponsored by Allergan Pharmaceuticals) “Tazarotene - A New Approach to Treating Psoriasis”

Hennepin County Medical Society, Annual Meeting, Minneapolis, MN, December, 1997. (Sponsored by Allergan Pharmaceuticals), “Tazarotene - A New Approach to Treating Psoriasis”

RPR Marketing Personnel – Eastern U.S., Washington, D.C., March, 1997. “Photosensitivity Questions Relating to Sparfloxacin Use”

Matrix Pharmaceutical, January, 1997. Training Video for Physicians of correct use of Accusite. Filmed for European use.

Page 4 of 5

SCIENTIFIC EXHIBITS: (Since 1993)

Society of Investigative Dermatology, Annual Meeting 2005. “Safety and Efficacy of a New Biologic Agent in the Treatment of Plaque-Type Psoriasis.” Poster. (Research supported by Astralis Ltd., Fairfield, NJ)

American Academy of Dermatology, Annual Meeting, February 2005. “Fluticasone Propionate (FP) Emulsion (0.05%): An Advance in Topical Preparations in TEH Treatment of Atopic Dermatitis.” Poster. (Research supported by Allergan, Inc., San Diego, CA).

American Academy of Dermatology, Annual Meeting, March 2003. “Examining Duration of Response and Rebound During Treatment with Efalizumab (anti-CD11a).” Poster. (Research supported by Genentech, Inc., South San Francisco, CA and XOMA (US)LLC, Berkeley, CA)

American Academy of Dermatology, Annual Meeting, March 2003. “Efalizumab (anti-CD11a) Retreatment: Final Results from an Open-Label Study in Psoriasis.” Poster. (Research supported by Genentech, Inc., South San Francisco, CA).

American Academy of Dermatology, Annual Meeting, February 2002. “Dose-Escalation Study of Oral Tazarotene in the Treatment of Moderate to Severe Plaque Psoriasis,” Poster. (Research supported by Allergan Pharmaceuticals, Irvine, CA)

American Academy of Dermatology, Annual Meeting, February 2002. “Comparing the Cost-Effectiveness of Tazarotene 0.1% Gel and Tretinoin 0.1% Microsponge in the Treatment of Facial Acne Vulgaris,” Poster. (Research supported by Allergan Pharmaceuticals, Irvine, CA)

American Academy of Dermatology, Annual Meeting, February 2000. “Therapy with Desloratadine for Chronic Idiopathic Urticaria Reduces Interference with Sleep and Daily Activities,” Poster. (Research supported by Schering Plough Research Institute, Kenilworth, NJ)

American Academy of Dermatology, Annual Meeting, February, 1996. “Treatment of Cutaneous Squamous Cell Carcinoma with Intralesional Fluorouracil/Epinephrine Injectable Gel: Canine Model and Human Pilot Study,” Poster. (Research supported by Matrix Pharmaceutical Inc., Menlo Park, CA)

American Academy of Dermatology, Annual Meeting, December 1993. “Treatment of Basal Cell Carcinoma with Intralesional 5-Fluorouracil Therapeutic Implant,” Poster. (Research supported by Matrix Pharmaceutical, Inc., Menlo Park, CA)

“Intralesional 5-Fluorouracil Therapeutic Implant for Treatment of Condylomata Acuminata.” Poster. (Research supported by Matrix Pharmaceutical, Inc., Menlo Park, CA)

Society for Investigative Dermatology, Spring 1993. Poster. “Double-blind Study of AGN 190168, A New Retinoid Gel, in the Topical Treatment of Acne Vulgaris.” (Research supported by Allergan Herbert, Irvine, CA)